Cargando…

Cerebral perfusion in the predementia stages of Alzheimer’s disease

OBJECTIVES: To investigate arterial spin-labelling (ASL) cerebral blood flow (CBF) changes in predementia stages of Alzheimer’s disease (AD). METHODS: Data were obtained from 177 patients with subjective complaints, mild cognitive impairment and AD from the Amsterdam Dementia Cohort. AD stages were...

Descripción completa

Detalles Bibliográficos
Autores principales: Binnewijzend, Maja A. A., Benedictus, Marije R., Kuijer, Joost P. A., van der Flier, Wiesje M., Teunissen, Charlotte E., Prins, Niels D., Wattjes, Mike P., van Berckel, Bart N.M., Scheltens, Philip, Barkhof, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712243/
https://www.ncbi.nlm.nih.gov/pubmed/26040647
http://dx.doi.org/10.1007/s00330-015-3834-9
_version_ 1782410029579632640
author Binnewijzend, Maja A. A.
Benedictus, Marije R.
Kuijer, Joost P. A.
van der Flier, Wiesje M.
Teunissen, Charlotte E.
Prins, Niels D.
Wattjes, Mike P.
van Berckel, Bart N.M.
Scheltens, Philip
Barkhof, Frederik
author_facet Binnewijzend, Maja A. A.
Benedictus, Marije R.
Kuijer, Joost P. A.
van der Flier, Wiesje M.
Teunissen, Charlotte E.
Prins, Niels D.
Wattjes, Mike P.
van Berckel, Bart N.M.
Scheltens, Philip
Barkhof, Frederik
author_sort Binnewijzend, Maja A. A.
collection PubMed
description OBJECTIVES: To investigate arterial spin-labelling (ASL) cerebral blood flow (CBF) changes in predementia stages of Alzheimer’s disease (AD). METHODS: Data were obtained from 177 patients with subjective complaints, mild cognitive impairment and AD from the Amsterdam Dementia Cohort. AD stages were based on diagnosis and cerebrospinal fluid biomarkers amyloid-β (Aβ) and total-tau (tau). General-linear-models were used to assess relationships between AD stages and total and regional CBF, correcting for age and sex. RESULTS: Decreasing CBF was related to more advanced AD stages in all supratentorial regions (p for trend < 0.05). Post-hoc testing revealed that CBF was lower in AD compared to controls and stage-1 predementia patients (i.e. abnormal Aβ and normal tau) in temporal and parietal regions, and compared to stage-2 predementia patients (i.e. abnormal Aβ and tau) in temporal regions. CBF values of stage-2 predementia patients were numerically in between those of stage-1 predementia patients and AD. CONCLUSION: The continuing decrease of CBF along the continuum of AD indicates the potential of ASL-CBF as a measure for disease progression. KEY POINTS: • Decreasing CBF relates to more advanced AD stages in all supratentorial regions. • The reduction of CBF does not reach a bottom level. • ASL-CBF has potential as a measure for disease progression in AD.
format Online
Article
Text
id pubmed-4712243
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47122432016-01-19 Cerebral perfusion in the predementia stages of Alzheimer’s disease Binnewijzend, Maja A. A. Benedictus, Marije R. Kuijer, Joost P. A. van der Flier, Wiesje M. Teunissen, Charlotte E. Prins, Niels D. Wattjes, Mike P. van Berckel, Bart N.M. Scheltens, Philip Barkhof, Frederik Eur Radiol Neuro OBJECTIVES: To investigate arterial spin-labelling (ASL) cerebral blood flow (CBF) changes in predementia stages of Alzheimer’s disease (AD). METHODS: Data were obtained from 177 patients with subjective complaints, mild cognitive impairment and AD from the Amsterdam Dementia Cohort. AD stages were based on diagnosis and cerebrospinal fluid biomarkers amyloid-β (Aβ) and total-tau (tau). General-linear-models were used to assess relationships between AD stages and total and regional CBF, correcting for age and sex. RESULTS: Decreasing CBF was related to more advanced AD stages in all supratentorial regions (p for trend < 0.05). Post-hoc testing revealed that CBF was lower in AD compared to controls and stage-1 predementia patients (i.e. abnormal Aβ and normal tau) in temporal and parietal regions, and compared to stage-2 predementia patients (i.e. abnormal Aβ and tau) in temporal regions. CBF values of stage-2 predementia patients were numerically in between those of stage-1 predementia patients and AD. CONCLUSION: The continuing decrease of CBF along the continuum of AD indicates the potential of ASL-CBF as a measure for disease progression. KEY POINTS: • Decreasing CBF relates to more advanced AD stages in all supratentorial regions. • The reduction of CBF does not reach a bottom level. • ASL-CBF has potential as a measure for disease progression in AD. Springer Berlin Heidelberg 2015-06-05 2016 /pmc/articles/PMC4712243/ /pubmed/26040647 http://dx.doi.org/10.1007/s00330-015-3834-9 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Neuro
Binnewijzend, Maja A. A.
Benedictus, Marije R.
Kuijer, Joost P. A.
van der Flier, Wiesje M.
Teunissen, Charlotte E.
Prins, Niels D.
Wattjes, Mike P.
van Berckel, Bart N.M.
Scheltens, Philip
Barkhof, Frederik
Cerebral perfusion in the predementia stages of Alzheimer’s disease
title Cerebral perfusion in the predementia stages of Alzheimer’s disease
title_full Cerebral perfusion in the predementia stages of Alzheimer’s disease
title_fullStr Cerebral perfusion in the predementia stages of Alzheimer’s disease
title_full_unstemmed Cerebral perfusion in the predementia stages of Alzheimer’s disease
title_short Cerebral perfusion in the predementia stages of Alzheimer’s disease
title_sort cerebral perfusion in the predementia stages of alzheimer’s disease
topic Neuro
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712243/
https://www.ncbi.nlm.nih.gov/pubmed/26040647
http://dx.doi.org/10.1007/s00330-015-3834-9
work_keys_str_mv AT binnewijzendmajaaa cerebralperfusioninthepredementiastagesofalzheimersdisease
AT benedictusmarijer cerebralperfusioninthepredementiastagesofalzheimersdisease
AT kuijerjoostpa cerebralperfusioninthepredementiastagesofalzheimersdisease
AT vanderflierwiesjem cerebralperfusioninthepredementiastagesofalzheimersdisease
AT teunissencharlottee cerebralperfusioninthepredementiastagesofalzheimersdisease
AT prinsnielsd cerebralperfusioninthepredementiastagesofalzheimersdisease
AT wattjesmikep cerebralperfusioninthepredementiastagesofalzheimersdisease
AT vanberckelbartnm cerebralperfusioninthepredementiastagesofalzheimersdisease
AT scheltensphilip cerebralperfusioninthepredementiastagesofalzheimersdisease
AT barkhoffrederik cerebralperfusioninthepredementiastagesofalzheimersdisease